Time:
0900 - 1030 PDT
1700 - 1830 UTC
Zoom Meeting Details
Hi there,
Jim Case is inviting you to a scheduled SNOMED International Zoom meeting.
Topic: EAG Conference call
Time: Jun 3, 2024 09:00 Pacific Time (US and Canada)
Join from PC, Mac, Linux, iOS or Android:
https://snomed.zoom.us/j/84094042590?pwd=2Z3a3ZjUAKxMEGZJlOdkl2YZcFUwhH.1
Password: 348039
International numbers available: https://snomed.zoom.us/u/kcIXuMl5Is
Attendees
Chair:
AG Members
Invitees:
Observers
Apologies:
Meeting Files:
Inline in agenda below
Objectives
- Obtain consensus on agenda items
Discussion items
Item | Description | Owner | Notes | Action |
---|---|---|---|---|
1 | Call to order and role call | This meeting is being recorded to ensure that important discussion points are not missed in the minutes. The recording will be available to the SNOMED International community. Joining the meeting by accepting the Zoom prompt declares that you have no objection to your comments being recorded | ||
2 | Conflicts of interest and agenda review | None recorded | ||
3 | TRAG discussion on "withdrawn" reason for inactivation | TRAG discussion page located at: Potential for adding a "withdrawn" reason for inactivated content Additional discussion page: Proposal to increase the level of metadata available for authors to log decisions made during content authoring Discussion: Need a clearer definition of what is meant by "active" content. Does it require an effective time to be active? One use case is translation or mapping to unreleased content. Would the notion of "never activated" be an acceptable alternative? Should this content ever be referenced in release files? While the daily build is a useful tool for previewing new content, it should not be used as a basis for "early" translation or mapping. The content should be used "at your own risk". Decision: General consensus is that prerelease content should not be used in production and thus the need for a "withdrawn" identifier is not needed. Need to be more explicit that prerelease content is subject to change or deletion. | ||
4 | Proposed policy for Assessment Instruments in SNOMED CT International release | Find attached a proposed policy related to Assessment instruments. Comments from the EAG members are solicted. Discussion: While the underlying principles are OK, it does not address the lack of ability to perform analytics on individual components of an assessment instrument. The key issue is the permission to use copyrighted material. Explanation of the reasons for adding the three types was provided. Usage data on the score observables was requested Decision: No issues with document as proposed. |
| |
5 | Briefing Note regarding the inactivation of therapeutic role groupers in the Medicinal Product hierarchy. | Informational only: Based on the discussion during the EAG meeting in London, the following Briefing note is distributed. Discussion: Concern about potential misunderstanding of the use of the term "role groupers". Suggest clearer phrasing to represent the fact that the inactivation are grouping concepts as opposed to the removal of role groups (or relationship groups) from the model. There is an ongoing issue with substances that are really products acting as groupers of other substances without a link to a product, which is correct. Another approach is needed. Decision: No objections to proposal | ||
6 | Updated Briefing note for transplantation procedures | An updated Briefing note for transplantation procedures of both solid organs and tissues is provided. Discussion: Questions to be sent to Nicola Ingram and Jim Case for discussion and clarification at a future EAG call Decision: | ||
7 | Reterming of "Percutaneous transluminal angioplasty " concepts | A proposed re-terming of angioplasty concepts due to inconsistencies that have lead to the creation of duplicate concepts. https://docs.google.com/presentation/d/1_Zv9sasfB-elzwNiZgUC-nrdmgx-Sew74pchOxqsyVM/edit?usp=sharinghttps://docs.google.com/presentation/d/1_Zv9sasfB-elzwNiZgUC-nrdmgx-Sew74pchOxqsyVM/edit?usp=sharing Discussion: - GC-287Getting issue details... STATUS Need consistent FSNs to represent variations.
There is sufficient evidence that many of the similar terms are in fact duplicates. Suggest that the action could be "compression" as it is the plaque that affected rather than a repair of the vessel. Because not all angioplasties are percutaneous, can we say that the existing angioplasty concepts represent a percutaneous transluminal angioplasty? Likewise, since not all PTAs are done using fluoroscopic guidance, can we make the assumption that the existing concepts all use fluoroscopic guidance? The concepts that were created back in 2002, all represented fluoroscopic guidance as ultrasound was not an option. We need a clear definition for existing concepts to determine whether we can inactivate concepts as duplicates. We can only model the content to the level that they are represented by the FSN. The generic term "angioplasty" is almost universally understood to be a PTA in the general literature. Question the need for a generic grouper as it can lead to misuse. This raises the issue around groupers that may be useful for analytics but should not be used in clinical records due to their inherent vagueness. (outstanding issue) Decision: | ||
8 | Change Surgical approach to Procedure approach | At the March 2024 EAG call, the group asked for an impact analysis of the change from Surgical approach to a more general Procedure approach. The results of that analysis were presented at the April 2024 meeting. At the April face-to-face meeting a list of non-surgical procedures that might benefit from this change was requested and is attached (download to view as spreadsheet). Discussion: Decision: 2024-04-16: Request to distribute list of non-surgical procedures affected by this change 2024-06-03: |
| |
9 | Bypass graft revision proposal | As requested from the EAG, a list of definitions has been developed that will guide content authors in the correct modeling of concepts related to bypass, bypass graft, shunt, etc.: Proposal for definition of concepts under 48537004 |Bypass graft (procedure)|.
Discussion: Decision: 2024-03-11 Comments will be added to the document by the EAG members. 2024-04-16: Proposed definitions will be revised based on input and resubmitted to the EAG for review. 2024-06-03: |
| |
10 | USING DEVICE vs. DIRECT DEVICE use in procedures (Information only) | Following discussion at the last EAG meeting and the document provided by Monique van Berkum (attached), new proposed definitions and examples for: USING DEVICE DIRECT DEVICE USING ACCESS DEVICE will be presented to the EAG for discussion at a future meeting Discussion: Decision: |
| |
11 | AOB | EAG | ||
12 | Next meeting | July 22, 2024 - pending availability of members |
2 Comments
Monica Harry
With regard to agenda Item no. 7, June 3rd, 2024:
410817004 |Dilation repair - action (qualifier value)| used only in angioplasty concepts therefore if decision is to inactivate, it will not have any impact on the classification, only on the model. At this time, no change.
Jim Case
The discussion in June seems to have moved away from the notion of angioplasty as a repair (even though plastic operations are "repair" procedures).